Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel...
Read more